软组织肿瘤患者的临床诊治要以患者获益为首要目标

Patients' benefit as the primary goal in clinical diagnosis and treatment of soft tissue tumors

虽然，起源于多种细胞成分构成的恶性软组织肿瘤发病率较低，仅占成人恶性肿瘤的0.73%～0.81%，15岁以下儿童的6.5%[1]。但是，在人体恶性肿瘤分类中最为复杂，国际通用的病理分类有19个组织类型和50余种不同的亚型。与常见恶性肿瘤相比，国内外专门从事研究和临床软组织肿瘤治疗的科研人员和临床医师较少，学术活动、相关论文和书籍等也不够普及，临床医师可获得的继续教育资源相对匮乏。因此，临床上误诊、误治现象较为普遍，使得初诊可能治愈的部分病例，最终发生严重的不良后果；部分复发和转移的患者，失去了再次治愈的机会；随意性手术、非计划性手术，过度化、放疗的现象也较为普遍，甚至任意开展分子靶向治疗、细胞免疫治疗等。

Although the incidence is low, the classification of malignant soft tissue tumors is the most complex in human malignant tumors. Compared with common malignant tumors, there are relatively fewer researchers engaging in the research and clinicians performing the treatment, and academic activities, related papers and books aren’t so popular. Therefore, clinical misdiagnosis and mistreatment are more common. Through the analysis of pathological types of soft tissue tumors, it is considered that localization diagnosis and qualitative diagnosis have laid a good foundation for the selection of reasonable and individualized comprehensive treatment methods. The appropriate time for surgery should be selected. With preoperative high-dose and high-density neoadjuvant chemotherapy and precise radiotherapy, combined with gene detection technology and targeted drug therapy, body surface soft tissue tumors that are hard to deal with before can be effectively cured. We are more confident in the treatment of recurrence and metastasis of soft tissue tumors, and furthermore, it’s beneficial for the patients.